间皮素与胰腺癌的免疫治疗  

Mesothelin and immunotherapy for pancreatic cancer

作　　者：高翔[1,2,3] 廖泉 Gao Xiang;Liao Quan(Department of General Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院 [2]北京协和医学院 [3]北京协和医院基本外科,100730

出　　处：《中华内分泌外科杂志》2019年第6期510-513,共4页Chinese Journal of Endocrine Surgery

基　　金：国家自然科学基金(81560387)。

摘　　要：作为恶性程度最高的肿瘤之一,胰腺癌及其治疗一直是世界范围内的难题。在手术率低,化疗敏感性差的背景下,免疫治疗成为了胰腺癌研究的重要方向之一,并有望为胰腺癌的治疗开辟新的途径。间皮素作为在胰腺癌中高表达而在正常组织中几乎不表达的细胞膜蛋白就成为了免疫治疗的一个理想靶点。本文就以间皮素为靶点的胰腺癌的免疫治疗方法及研究进展做一综述。As one of the most lethal malignancies,pancreatic cancer and its therapy remains a big problem all around the world.With the few candidates for surgery and the poor outcome for chemotherapy,the immunotherapy becomes one important direction.Mesothelin,a membrane protein,expresses at low levels in normal tissues,but is re-expressed at a high frequency in pancreatic cancer,which makes mesothelin an ideal target for immunotherapy.This review summarizes the progression of mesothein-targeted immunotherapy for pancreatic cancer.

关 键 词：间皮素 胰腺癌 免疫治疗 

分 类 号：R735.9[医药卫生—肿瘤]